Technology Commercialization Group, LLC (TCG), a healthcare consultancy based in Research Triangle Park, North Carolina has signed an agreement to represent Optimapharm d.o.o., as it enters the US market. Optimapharm is a leading Southeastern European (SEE) based clinical research organization (CRO). The Company is headquartered in Zagreb, Croatia with additional offices in Belgrade, Serbia covering unique SEE clinical centers. Using their highly trained managers, Optimapharm has conducted more than 75 clinical studies since its inception in 2006 and serves six (6) SEE countries (Croatia, Slovenia, Serbia, Bosnia and Herzegovina, Montenegro and FYR Macedonia) as well as 22 other European countries through strategic partnerships.
“We are the leading CRO in our region having extensive experience in Oncology, Psychiatry/Central Nervous System, Cardiovascular and Metabolic Diseases. Our highly trained investigators in six countries can deliver a naïve treatment population of more than 25 million patients to US clinical researchers.”